Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Rocket Pharmaceuticals Inc. (RCKT:NASDAQ), powered by AI.
Rocket Pharmaceuticals Inc. is currently trading at $3.86. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Rocket Pharmaceuticals Inc. on Alpha Lenz.
Rocket Pharmaceuticals Inc.'s P/E ratio is -1.4.
“Rocket Pharmaceuticals Inc. trades at a P/E of -1.4 (undervalued) with modest ROE of -54.1%.”
Ask for details →Rocket Pharmaceuticals Inc. is a biotechnology company dedicated to developing life-changing gene therapies for rare and often devastating genetic diseases. The company's primary focus is on delivering potentially curative treatments for patients who have limited or no alternatives. With an emphasis on rare pediatric diseases, Rocket Pharmaceuticals strives to address significant unmet medical needs by advancing innovative therapies through its pipeline. Notably, the company prioritizes conditions such as Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency, among others. Rocket Pharmaceuticals is significant in the financial market due to its pioneering efforts in the field of gene therapy, which represents a vital sector in the broader biotechnology industry. The company is at the forefront of transforming gene therapy from a scientific possibility into a viable treatment, thereby playing a crucial role in the ongoing narrative of medical innovation and personalized medicine.
“Rocket Pharmaceuticals Inc. trades at a P/E of -1.4 (undervalued) with modest ROE of -54.1%.”
Ask for details →Rocket Pharmaceuticals Inc. (ticker: RCKT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 299 employees. Market cap is $366M.
The current price is $3.86 with a P/E ratio of -1.41x and P/B of 0.79x.
ROE is -54.14%.